A5014988350- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Cancer, Lipids, and Metabolism
- Intraperitoneal and Appendiceal Malignancies
- Advanced Radiotherapy Techniques
- Medical Imaging Techniques and Applications
- Colorectal and Anal Carcinomas
- Neuroendocrine Tumor Research Advances
- Esophageal Cancer Research and Treatment
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Radiation Therapy and Dosimetry
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Hypoxia, and Metabolism
- Gastrointestinal Tumor Research and Treatment
- MRI in cancer diagnosis
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Treatments and Studies
- Tumors and Oncological Cases
- Head and Neck Cancer Studies
- Soft tissue tumor case studies
- Ferroptosis and cancer prognosis
- Renal cell carcinoma treatment
- Cancer and Skin Lesions
Rigshospitalet
2009-2023
University of Copenhagen
2006-2022
Copenhagen University Hospital
2007-2020
4004 Background: The optimum combination curative approach to locally advanced adenocarcinoma of the esophagus and esophago-gastric junction (AEG) is unknown. A key question whether neoadjuvant multimodal therapy, specifically CROSS (carboplatin/paclitaxel, 41.4Gy radiation therapy), superior peri-operative chemotherapeutic regimens including modified MAGIC (epirubicin, cisplatin (oxaliplatin), 5-FU (capecitabine)) more latterly FLOT (docetaxel, 5-FU, leucovorin, oxaliplatin). Neo-AEGIS was...
295 Background: The optimum combination curative approach to locally advanced adenocarcinoma of the esophagus and esophago-gastric junction (AEG) remains controversial, specifically whether multimodal therapy or perioperative chemotherapy is superior. Neo-AEGIS was designed as first randomized clinical trial (RCT) directly compare CROSS regimen (carboplatin/paclitaxel, 41.4Gy radiation therapy) with a modified MAGIC (epirubicin, cisplatin (oxaliplatin), 5-FU (capecitabine)) (pre-2018) more...
The objective of this prospective study was to compare the sensitivities and specificities combined 2-(<sup>18</sup>F) fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (PET/CT), abdominal/transvaginal ultrasound (US), CT for diagnosing recurrent ovarian cancer (OC) evaluate influence PET/CT on referral patients with solitary recurrence secondary cytoreductive surgery. From April 2005 November 2007, 60 were consecutively included 68 times. inclusion criteria remission...
LBA3514 Background: Organ preserving treatment strategies based on chemoradiotherapy may spare rectal cancer patients of major surgery and stoma. We suggest substantially improved tumor control by increasing the radiotherapy dose, without significant increase in rate late effects. designed a prospective phase II trial to test high-dose low for organ preservation multicenter setting. Methods: enrolled with localized T1-3 N0-1 M0 within 6 cm from anal verge performance status 0-2. Any N1-nodes...
Introduction. In patients with advanced ovarian cancer undergoing preoperative PET/CT, we investigated the prognostic value of SUV in primary tumor and evaluated for predicting incomplete cytoreduction (macroscopic residual tumor). Material methods. From September 2004 to August 2007, 201 consecutive a pelvic Risk Malignancy Index (RMI) > 150 based on serum CA-125, ultrasound examinations menopausal state, underwent PET/CT within two weeks prior standard surgery/debulking tumor. At two-year...
To evaluate the role of 2-deoxy-2-(F)fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) for selecting patients with extensive ovarian cancer (OC) neoadjuvant chemotherapy by evaluating predictors overall survival in stage IIIC/IV OC.From September 1, 2004, to November 20, 2011, 514 consecutive a pelvic tumor underwent preoperative PET/CT; 179 had OC. Patients' characteristics were collected from 153 OC who primary surgery. In 152 OC, clinical and PET/CT...
To evaluate intrafractional fiducial marker position variations during stereotactic body radiotherapy (SBRT) in patients treated for liver metastases visually guided, voluntary deep inspiration breath-hold (DIBH).10 with implanted markers were studied. Respiratory coaching visual guidance was used to ensure comfortable breath-holds SBRT imaging and delivery. Three DIBH CTs acquired treatment planning. Pre- post-treatment CBCTs each of the three fractions. Per-fraction evaluated on planar 2D...
Abstract Purpose: To determine if the level of apolipoprotein A1, hepcidin, transferrin, inter‐α trypsin IV internal fragment, transthyretin (TT), connective‐tissue activating protein 3 (CTAP3), serum amyloid β‐2 microglobulin (B2M) might have impact on overall and progression‐free survival for ovarian cancer (OC) patients. Experimental design: Serum from 150 OC patients was tested using SELDI‐TOF‐MS. Results: A proteomic prognostic index (xb‐pro) constructed regression coefficients based...
The purposes of this study were to confirm previously found candidate epithelial ovarian cancer biomarkers in urine and compare a paired serum biomarker panel from the same cohort with regard receiver operating characteristic curve (ROC) area under ROC (AUC) values.Four significant confirmed among 130 pelvic mass patients present study. four form potential panel. From cohort, was compared panel, consisting seven proteins/peptides, OvaRI.Multivariate analysis demonstrated differentiation...
We investigate the accuracy of intensity-based deformable image registration (DIR) for tumor localization in liver stereotactic body radiotherapy (SBRT). included 4DCT scans to capture breathing motion eight patients receiving SBRT metastases within a retrospective clinical study. Each patient had three fiducial markers implanted. The and were delineated mid-ventilation phase, their positions other phases estimated with registration. tested referenced sequential registrations strategies....
The objective of this prospective study was to evaluate CA-125 and a 7-marker panel as predictors incomplete primary cytoreduction in patients with stage III/IV ovarian cancer (OC). From September 2004 January 2008, serum from 201 referred surgery for pelvic tumor analyzed CA-125. In addition, 7 biomarkers using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. These were combined into single-valued ovarian-cancer-risk index (OvaRI). OvaRI evaluated 75 receiver...
Key Clinical Message Survival of stage 4 ganglioneuroblastoma ( GNB ) patients is poor; no reports exist surviving up to 5 years (1, 2). We report the clinical and therapeutic course a patient with beyond expectations due multimodal treatment approach incorporating new technologies in cancer diagnostic treatment.
ObjectivesIn a randomized phase II trial, twice daily (BID) thoracic radiotherapy (TRT) of 60 Gy/40 fractions improved survival compared with 45 Gy/30 in limited stage small-cell lung cancer (LS SCLC). Notably, the higher dose did not cause more toxicity. Here we present health related quality life (HRQoL) reported by trial participants during first 2 years.Materials and methods170 patients were 1:1 to TRT Gy or concurrently cisplatin/etoposide chemotherapy. The 150 who commenced completed...
22060 Background: Pre-operative cancer stage and grade are inadequate predictors of survival in patients with ovarian cancer. Methods: serum samples were collected IRB approval a study overseen by Rigshospitalet, Denmark, from 82 consecutive diagnosed invasive epithelial Equalizer bead fractionation SELDI-TOF-MS profiling was performed to identify biomarkers that might separate short-term survivors long-term survivors. In addition, 7 marker proteomic pattern tested on these samples. Results:...
e17609 Background: In Greenland, the incidence of lung cancer (LC) is now as high in other Nordic countries; 59.8/100,000 for men and 43.9/100.000 women. 2004, oncological treatment LC following Danish guidelines became available to patients Greenland. We performed a retrospective evaluation results overall survival (OS) after first six years Methods: From September 2004 August 2010, 173 with were referred at Queen Ingrid’s Hospital Nuuk. OS was calculated interval from date diagnosis death...